In bone, GLP-1 binding to its receptor promotes bone marrow mesenchymal stem cell osteoblast differentiation and inhibits its differentiation into fat cells, thereby promoting bone formation and improving osteoporosis [15]
It acts on both pathways to suppress appetite and improve insulin resistance
Whats even more confusing is that it takes about three months after exposure to the stress i.e., the GLP-1 weight loss to see this happen
however, side effects might occur, particularly during the first few weeks of treatment or following a dosage increase
The acquisition of Zava will bring Hims & Hers to over a million customers in the European market and launch it for the first time in Germany, France and Ireland
In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
